MYC and lymphoma: Patients with lymphoma cells co-expressing MYC and BCL-2 have been shown to respond better to ABT-737 (a selective inhibitor of BCL-2, BCLxL, and BCLw) (Figure 2), showing that BCL-2 has a critical role in DHL [66, 67].